These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1914378)

  • 1. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.
    Bickel U; Thomsen T; Weber W; Fischer JP; Bachus R; Nitz M; Kewitz H
    Clin Pharmacol Ther; 1991 Oct; 50(4):420-8. PubMed ID: 1914378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice.
    Bickel U; Thomsen T; Fischer JP; Weber W; Kewitz H
    Neuropharmacology; 1991 May; 30(5):447-54. PubMed ID: 1865992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans.
    Mihailova D; Yamboliev I; Zhivkova Z; Tencheva J; Jovovich V
    Pharmacology; 1989; 39(1):50-8. PubMed ID: 2587617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6.
    Bachus R; Bickel U; Thomsen T; Roots I; Kewitz H
    Pharmacogenetics; 1999 Dec; 9(6):661-8. PubMed ID: 10634129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.
    Thomsen T; Bickel U; Fischer JP; Kewitz H
    Eur J Clin Pharmacol; 1990; 39(6):603-5. PubMed ID: 2095347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue distribution of galantamine and galantamine-related radioactivity after single intravenous and oral administration in the rat.
    van Beijsterveldt L; Geerts R; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2004; 54(2):85-94. PubMed ID: 15038457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.
    Thomsen T; Kewitz H
    Life Sci; 1990; 46(21):1553-8. PubMed ID: 2355800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species.
    Monbaliu J; Verhaeghe T; Willems B; Bode W; Lavrijsen K; Meuldermans W
    Arzneimittelforschung; 2003; 53(7):486-95. PubMed ID: 12918214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine.
    Thomsen T; Kaden B; Fischer JP; Bickel U; Barz H; Gusztony G; Cervos-Navarro J; Kewitz H
    Eur J Clin Chem Clin Biochem; 1991 Aug; 29(8):487-92. PubMed ID: 1954303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galanthamine.
    Fulton B; Benfield P
    Drugs Aging; 1996 Jul; 9(1):60-5; discussion 66-7. PubMed ID: 8818586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats.
    Mihailova D; Yamboliev I
    Pharmacology; 1986; 32(6):301-6. PubMed ID: 3725886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes.
    Li W; Zhou Y; Zhao N; Hao B; Wang X; Kong P
    Environ Toxicol Pharmacol; 2012 Sep; 34(2):272-279. PubMed ID: 22613079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients.
    Westra P; van Thiel MJ; Vermeer GA; Soeterbroek AM; Scaf AH; Claessens HA
    Br J Anaesth; 1986 Nov; 58(11):1303-7. PubMed ID: 3778794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro metabolism of galanthamine hydrobromide (Nivalin) by rat and rabbit liver homogenate.
    Mihailova D; Velkov M; Zhivkova Z
    Eur J Drug Metab Pharmacokinet; 1987; 12(1):25-30. PubMed ID: 3609070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
    Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM
    J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of galanthamine as a reversible inhibitor of cholinesterase].
    Vasilenko ET; Tonkopiĭ VD
    Biokhimiia; 1974; 39(4):701-3. PubMed ID: 4441566
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers.
    Imbimbo BP; Licini M; Schettino M; Mosca A; Onelli E; Zecca L; Giustina A
    J Clin Pharmacol; 1995 Mar; 35(3):285-90. PubMed ID: 7608318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
    Goh CW; Aw CC; Lee JH; Chen CP; Browne ER
    Drug Metab Dispos; 2011 Mar; 39(3):402-11. PubMed ID: 21148081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics.
    Cutler NR; Seifert RD; Schleman MM; Sramek JJ; Szylleyko OJ; Howard DR; Barchowsky A; Wardle TS; Brass EP
    Clin Pharmacol Ther; 1995 Jul; 58(1):54-61. PubMed ID: 7628183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.